A retrospective study of cabozantinib in the patients with metastatic clear cell renal cell carcinoma (mccRCC) in real world settings

Trial Profile

A retrospective study of cabozantinib in the patients with metastatic clear cell renal cell carcinoma (mccRCC) in real world settings

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Mar 2018 New trial record
    • 10 Feb 2018 Results assessing safety and efficacy of cabozantinib in real world setting, presented at the 2018 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top